文献速递肿瘤 PET/CT神经核医学

以CXCR4靶向正电子发射断层显像示踪剂[68Ga]Pentixafor评估眼眶结外边缘区淋巴瘤患者的治疗反应

Response assessment with the CXCR4-directed positron emission tomography tracer [68Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities.
PubMed 文献 · EJNMMI Res · 2017-06-02

本文以概念验证方式,对一名眼眶结外边缘区淋巴瘤(MZL)患者在诊断时及治疗后进行[68Ga]Pentixafor PET显像,并与常规[18F]FDG PET比较;MRI确定的淋巴瘤病灶在诊断时对该示踪剂呈高摄取,治疗后摄取下降;作者提出[68Ga]Pentixafor显像可能是用于靠近或位于中枢神经系统(CNS)肿瘤的诊断工具,并建议在临床试验中研究。

要点

  • 眼眶结外边缘区淋巴瘤病灶在诊断时对[68Ga]Pentixafor呈高摄取,治疗后摄取下降。
  • [68Ga]Pentixafor在外周肿瘤病灶诊断性PET显像中较[18F]FDG有局限性。
  • 作者提出[68Ga]Pentixafor显像可能是靠近或位于CNS肿瘤的潜在诊断工具。

核心结论

  • 作者提出,以[68Ga]Pentixafor显像CXCR4可能是靠近或位于CNS肿瘤的潜在诊断工具,并建议在临床试验中研究。

研究设计与样本

  • 概念验证性研究,对一名眼眶结外边缘区淋巴瘤患者在诊断时及治疗后进行[68Ga]Pentixafor PET显像,并与常规[18F]FDG PET比较。

主要发现

  • 与常规[18F]FDG PET相比,MRI确定的淋巴瘤病灶在诊断时对[68Ga]Pentixafor呈高示踪剂摄取,且该摄取在治疗后下降。

关键数值与推荐

  • [68Ga]Pentixafor在外周肿瘤病灶诊断性PET显像中较[18F]FDG有局限性。

临床怎么用

  • 作者提出[68Ga]Pentixafor显像CXCR4可能是靠近或位于CNS肿瘤的潜在诊断工具,并建议在临床试验中研究。

局限性

  • 原文报告[68Ga]Pentixafor在外周肿瘤病灶诊断性PET显像中较[18F]FDG有局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CXCR4 belongs to the family of chemokine receptors. Together with its sole known ligand CXCL12 (SDF-1alpha), it has a pivotal role during organogenesis and for homing of hematopoietic stem cells. CXCR4 is overexpressed in various malignancies, and this is often associated with poor prognosis. Therefore, molecular imaging of CXCR4 bears a great potential for diagnostics and selecting patients for CXCR4-directed therapies. The CXCR4-directed positron emission tomography (PET) tracer [68Ga]Pentixafor has been shown to visualize CXCR4 expression in various malignancies in vivo. Whereas this tracer has limitations compared to 18F-Fluorodeoxyglucose ([18F]FDG) in diagnostic PET imaging in peripheral tumour lesions, it might add valuable information in routine diagnostics and response assessment of tumours in close proximity to the central nervous system (CNS) and malignancies within this organ. As a proof-of-concept, we performed [68Ga]Pentixafor PET imaging in a patient with extranodal marginal zone lymphoma (MZL) of the orbital cavities at diagnosis and for post-therapy response assessment. Compared to routinely conducted [18F]FDG PET, the lymphoma lesions determined by magnetic resonance imaging (MRI) showed high tracer accumulation at diagnosis, which decreased upon treatment. We therefore propose that imaging of CXCR4 with [68Ga]Pentixafor is a potential diagnostic tool for tumours close to or within the CNS and suggest this being studied in clinical trials.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Herhaus P, Habringer S, Vag T, et al. Response assessment with the CXCR4-directed positron emission tomography tracer [68Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities. EJNMMI Res. 2017. PMID: 28577295. doi:10.1186/s13550-017-0294-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。